Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals(KNSA)

MA - Lexington
Pharmaceutical
WebsiteLinkedInCareers Page

Focus: Biologics, Monoclonal Antibodies

Kiniksa Pharmaceuticals is a life sciences company focused on Biologics, Monoclonal Antibodies.

Neurology
Funding Stage
PUBLIC
Open Jobs
20

Products & Portfolio (1)

ARCALYST
rilonacept
LOE Approaching
SINGLE-USE · VIAL
interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β) cytokine trap. Rilonacept blocks IL-1 signaling by acting as a soluble decoy receptor that binds both IL-1α and IL-1β and prevents its interaction with cell surface receptors. Rilonacept also binds interleukin-1 receptor antagonist (IL-1ra). The equilibrium dissociation constants for rilonacept binding to IL-1α, IL-1β, and IL-1ra were 1.4 pM, 0.5 pM, and 6.1 pM, respectively. CAPS refers to rare genetic syndromes generally caused by mutations in the NLRP-3 [nucleotide-binding domain, leucine rich family (NLR), pyrin domain containing 3] gene (also known as Cold-Induced Autoinflammatory Syndrome-1 [ CIAS1 ]). CAPS disorders are inherited in an autosomal dominant pattern with male and female offspring equally affected. Features common to all disorders include fever, urticaria-like rash, arthralgia, myalgia, fatigue, and conjunctivitis. In most cases, inflammation in CAPS is associated with mutations in the NLRP-3 gene, which encodes the protein cryopyrin, an important component of the inflammasome. Cryopyrin regulates the protease caspase-1 and controls the activation of interleukin-1 beta (IL-1β). Mutations in NLRP-3 result in an overactive inflammasome, resulting in excessive release of activated IL-1β that drives inflammation. DIRA is an autoinflammatory, autosomal recessive disorder caused by loss of function mutations in the IL1RN gene, which encodes IL-1 receptor antagonist (IL-1ra), resulting in unopposed signaling of the proinflammatory cytokines IL-1α and IL-1β through the IL-1 receptor. Interleukin-1 (IL-1) is a key cytokine that mediates the pathophysiology of many inflammatory processes, and it has been implicated as a causative factor in pericarditis. IL-1α and IL-1β bind to the universally expressed cell surface receptor, IL-1 Receptor type-1, triggering a cascade of inflammatory mediators. Pre-formed IL-1α is released by damaged/inflamed pericardial cells and may contribute to the maintenance and amplification of inflammation via activation of the NLRP3 inflammasome, which then augments the inflammatory response by production of IL-1β in a cascade amplification system.
Cryopyrin-Associated Periodic Syndromes (CAPS)including Familial Cold Autoinflammatory Syndrome (FCAS)Muckle-Wells Syndrome (MWS) in adults+3 more
2008
30

Pipeline & Clinical Trials

REgiStry Of the NAtural History of recurreNt periCarditis in pEdiatric and Adult Patients
Recurrent Pericarditis
N/A
Clinical Trials (1)
NCT04687358REgiStry Of the NAtural History of recurreNt periCarditis in pEdiatric and Adult Patients
N/A
Phase 1
Clinical Trials (1)
NCT04497662Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of KPL-404 in Healthy Subjects
Phase 1
Phase 2
Clinical Trials (1)
NCT07288216Transition to KPL-387 Monotherapy Dosing & Administration Study
Phase 2
Mavrilimumab
COVID 19
Phase 2
Clinical Trials (1)
NCT04492514Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
Phase 2
Phase 2
Clinical Trials (1)
NCT03980522A Pilot Study of KPL-914 in Recurrent Pericarditis
Phase 2
Phase 2
Clinical Trials (1)
NCT03827018KPL-301 for Subjects With Giant Cell Arteritis
Phase 2
Mavrilimumab
COVID 19
Phase 2
Clinical Trials (1)
NCT04399980Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
Phase 2
Phase 2
Clinical Trials (1)
NCT06531395A Study to Evaluate the Efficacy and Safety of Abiprubart in Participants With Sjögren's Disease
Phase 2
Phase 2
Clinical Trials (1)
NCT03816891Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis
Phase 2
Phase 2
Clinical Trials (1)
NCT05198310Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor
Phase 2
Mavrilimumab
COVID-19
Phase 2
Clinical Trials (1)
NCT04463004Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
Phase 2
Phase 2
Clinical Trials (1)
NCT03858634A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases
Phase 2
Phase 2/3
Clinical Trials (1)
NCT07010159Phase 2/3 Study of KPL-387 in Recurrent Pericarditis
Phase 2/3
mavrilimumab
COVID
Phase 2/3
Clinical Trials (1)
NCT04447469Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation
Phase 2/3
Phase 3
Clinical Trials (1)
NCT03737110Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent Pericarditis
Phase 3

Open Jobs (20)

Clinical Trial Liaison

Zug, ZG, CH
5d ago

Clinical Sales Specialist - Omaha, NE

Anywhere, XX, US
Commercial
1w ago
$180K - $200K/yr

Vice President, Human Resources

Lexington, MA, US
Management
1w ago
$310K - $345K/yr

Senior Manager, Formulation and Drug Product Development

Lexington, MA, US
Management
1w ago
$174K - $191K/yr

Associate Director, Downstream Process Development & Manufacture

Lexington, MA, US
1w ago
$190K - $205K/yr

Director, Regulatory Affairs Writing

Lexington, MA, US
Management
1w ago
$223K - $236K/yr

Senior Clinical Project Manager

Lexington, MA, US
2w ago
$160K - $180K/yr

Regional CSS - San Fernando Valley

Anywhere, XX, US
Commercial
2w ago
$180K - $200K/yr

Clinical Trial Liaison

Lexington, MA, US
3w ago
$128K - $142K/yr

Regional CSS-Coastal Southeast

Anywhere, XX, US
Commercial
3w ago
$180K - $200K/yr

Manager, Quality Control Operations

Lexington, MA, US
Professional
3w ago
$129K - $144K/yr

Vice President, CMC Strategy

Lexington, MA, US
3w ago
$300K - $346K/yr

Manager, Device Development and Manufacturing

Lexington, MA, US
Professional
3w ago
$134K - $152K/yr

Director, Omnichannel & Marketing Capabilities/AI

Lexington, MA, US
3w ago
$230K - $240K/yr

Director, Omnichannel Digital Marketing

Lexington, MA, US
4w ago
$230K - $240K/yr

Regional CSS - Northern Plains

Anywhere, XX, US
Commercial
4w ago
$180K - $200K/yr

Clinical Sales Specialist - Rochester, MN

Anywhere, XX, US
Commercial
1mo ago
$180K - $200K/yr

Director, Patient Services & Vendor Strategy

Lexington, MA, US
1mo ago
$225K - $235K/yr

Associate Director, Clinical Operations - ZUG

Zug, ZG, CH
1mo ago

Executive Director, Program Lead

Lexington, MA, US
1mo ago
$300K - $330K/yr
Interview Prep Quick Facts
Portfolio: 1 approved product, 15 clinical trials
Top TAs: Immunology, Dermatology, Infectious Diseases
SEC Filings: 2 available
Open Roles: 20 active jobs
Portfolio Health
LOE Approaching1 (100%)
1 total products
Therapeutic Area Focus
Immunology
2 pipeline
Dermatology
1 pipeline
Marketed
Pipeline

Financials (FY2025)

Revenue
$270M23%
R&D Spend
$76M(28%)16%
Net Income
$14M
Cash
$184M
Source: SEC 10-K Filing

Hiring Trend

Actively Hiring
20
Open Roles
+23
Added
-3
Filled/Removed

Based on last 4 crawl cycles